The first lot of pharmaceutical glass vials are ready for shipment from Stevanato Group’s plant in Monterrey, Mexico, to Clover, China.
Clover is one of the nine COVID-19 vaccine candidates Stevanato Group’s partner CEPI (Coalition for Epidemic Preparedness Innovations) is supporting. Through their partnership, CEPI has provided up to 328 million USD in funding to advance the development of Clover’s protein-based S-Trimer COVID-19 vaccine candidate.
The investment has supported preclinical studies and Phase I clinical trials and will now fund a global pivotal Phase 2/3 efficacy clinical trial, additional clinical studies in special populations, such as people with autoimmune conditions and pregnant women, and will continue to scale-up manufacturing of doses so that the vaccine is available without delay, should it be proven safe and effective in clinical testing.
The supply of Stevanato Group’ glass vials to Clover in China brings together two main pillars of CEPI’s work in COVID-19: vaccine development and manufacturing.
